Navigation Links
Vermillion Announces Issuance of European Patent
Date:6/2/2010

nostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or the timing of Vermillion's relisting its shares on the NASDAQ Global Market or on other national securities exchange; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.   In addition, any financial information presented in this press release is unaudited and subject to adjustment following Vermillion's internal review and quarterly processes as well as annual audit.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
2. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
3. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
4. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
5. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
6. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
7. Vermillion Announces Receipt of NASDAQ Panel Decision
8. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
9. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
10. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
11. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... -- Biostar Pharmaceuticals,Inc. ("Biostar" or the "Company") (OTC Bulletin Board: BSPM) today ... Highlights for Year Ended December 31, 2008:, ... from $15.9 million, for 2007., ... as compared to, $3,963,524 in 2007., ...
... Aerovance Inc. today announced that it has secured ... transactions since formation in 2004, the company has raised ... debt financing.This financing round, which consists of two tranches, ... the full pro rata participation of existing investors Apax ...
... will be holding its 22nd Annual Conference, May 4-7, 2009 at ... ... MN (PRWEB) April 7, 2009 -- The American Filtration and ... May 4-7, 2009 at the Sheraton Hotel in Bloomington Minnesota. ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 2Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 4Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 5Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 6Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
(Date:4/17/2014)... densely forested and most densely populated quadrant of the ... values and practices. Disturbances associated with those needs, such ... have set the stage for management issues of considerable ... The report Five anthropogenic factors that will radically ... United States was published recently by the ...
(Date:4/17/2014)... for chili peppers. Information about archaeological remains of ancient ... the appearance of words for chili peppers in ancient ... and highlight the value of multi-proxy data analysis. Their ... nine papers presented in a special feature issue of ... on plant and animal domestication edited by Dolores ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Toshisada Nishida is this year,s winner of the International ... research and contributions to primatology. The award was presented ... Scotland, on 7 August 2008. Nishida will also be ... ape and human evolution by the Leakey Foundation. He ...
... In a study on fetal alcohol syndrome, researchers were ... cells in a key area of the fetal brain ... acidic environment that alcohol produces. The cerebellum, the portion ... muscle coordination, is particularly vulnerable to injury from alcohol ...
... N.J., July 28 Ikaria Holdings, Inc., a ... the,U.S. Food and Drug Administration (FDA) has granted ... in the reduction of the incidence and,severity of ... organ,transplantation., Ralf Rosskamp, M.D., Executive Vice President ...
Cached Biology News:Springer editor Toshisada Nishida winner of 2 prestigious primatology awards 2Researchers block damage to fetal brain following maternal alcohol consumption 2Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants 2